These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24050676)

  • 1. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.
    Sultan SM; Ng KP; Edwards JC; Isenberg DA; Cambridge G
    Clin Exp Rheumatol; 2008; 26(5):887-93. PubMed ID: 19032824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
    Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
    Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
    Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
    García Hernández FJ; Chinchilla Palomares E; Castillo Palma MJ; González Pulido C; Ocaña Medina C; Sánchez Román J
    Med Clin (Barc); 2010 Jul; 135(6):256-9. PubMed ID: 20537666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
    Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
    Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
    López De Padilla CM; Crowson CS; Hein MS; Strausbauch MA; Aggarwal R; Levesque MC; Ascherman DP; Oddis CV; Reed AM
    Clin Exp Rheumatol; 2015; 33(5):655-63. PubMed ID: 26446265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.
    Allenbach Y; Guiguet M; Rigolet A; Marie I; Hachulla E; Drouot L; Jouen F; Jacquot S; Mariampillai K; Musset L; Grenier P; Devilliers H; Hij A; Boyer O; Herson S; Benveniste O
    PLoS One; 2015; 10(11):e0133702. PubMed ID: 26539981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.
    Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J
    Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.